IL2 and adenocarcinoma: To decouple donor-derived biological heterogeneity from technical validation, we subsequently employed IL-2-stimulated Natural Killer cells (NK92<sup>IL2</sup>) as a standardized effector population against U87<sup>GFP</sup>, K562 leukemia, and LS174T adenocarcinoma targets.